Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lefukang Capsule
- Development stage
- Phase 3
- Lead developer
- Chongqing Searainbow Pharmaceutical
- Administration
- Oral
01
Overview
Lefukang Capsule is a Traditional Chinese Medicine (TCM) developed by Chongqing Searainbow Pharmaceutical for the treatment of chronic pelvic pain resulting from the sequelae of pelvic inflammatory disease (PID). It is specifically indicated for patients presenting with the TCM pattern of qi stagnation and blood stasis. The formulation aims to promote blood circulation, resolve stasis, and alleviate pain. It has been evaluated in a randomized, double-blind Phase 3 clinical trial in China, comparing its efficacy and safety against Kunfukang Capsule, another TCM product used for similar indications.
- Brand names
- Lefukang Capsule
- Other names
- Lefukang乐妇康胶囊
02
Targets
PTC (50S ribosomal peptidyl transferase center)
Beyond the preview
Go deeper on Lefukang Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lefukang Capsule.